Retatrutide's Phase 3 Package Is Complete: What Lilly's Q2 2026 Earnings Revealed
TL;DR: Lilly's Q2 2026 earnings (5 Aug) confirm retatrutide's Phase 3 package is complete; tirzepatide now outsells Novo's semaglutide by $10bn+.
What Did Eli Lilly Say About Retatrutide in Its Q2 2026 Earnings?
Alongside its second-quarter 2026 financial results, published 5 August 2026, Eli Lilly confirmed that retatrutide's Phase 3 clinical data package is now complete — covering obesity, obstructive sleep apnea and knee osteoarthritis pain — and ready to support global regulatory submissions.[1] The company reiterated that its Biologics License Application (BLA) to the FDA remains targeted for Q1 2027, unchanged from the delay disclosed in late July 2026 (see our coverage of that filing-timeline update).[4]
CEO David Ricks framed retatrutide as central to the company's next growth phase, stating in the earnings release that with the compound's "complete clinical data package in hand, new manufacturing capacity coming online, and exciting new assets entering our pipeline through business development, Lilly's future, after 150 years, has never been brighter."[1] Retatrutide itself is still investigational and not approved for use anywhere; Velox Peptides continues to supply it as an HPLC-verified (≥99% purity) lyophilised reagent for in vitro research use only. View the Retatrutide product page →
How Much Did Tirzepatide (Mounjaro and Zepbound) Sell in Q2 2026?
Lilly's already-licensed dual GLP-1/GIP agonist, tirzepatide, drove the bulk of the quarter's growth. Worldwide Mounjaro (type 2 diabetes) revenue reached $9.9bn, up 91% year-on-year, split between $4.8bn in the US (+45%) and $5.2bn outside the US (+172%). US Zepbound (obesity) revenue reached $4.9bn, up 44%.[1] Combined, the two brands generated roughly $14.8bn for the quarter, pushing total Lilly revenue up 48% to about $23.0bn and reported diluted EPS up 26% to $7.94 ($8.38 non-GAAP, +33%).[2] Lilly raised its full-year 2026 revenue guidance to $85–87bn, from $82–85bn previously, and its shares rose sharply on the results.[2]
How Did Novo Nordisk's Q2 2026 Results Compare?
Novo Nordisk revenue: approximately $12.1bn, beating analyst forecasts of roughly $10.94bn; adjusted operating profit 33.4bn DKK (≈$5.15bn), up 11% at constant exchange rates.[5]
Diabetes/obesity portfolio: Novo's combined franchise brought in about $9.16bn for the quarter, versus Lilly's roughly $14.8bn from Mounjaro and Zepbound alone.[4]
Wegovy and Ozempic: US Wegovy injectable sales fell 22% at constant exchange rates, while Ozempic sales rose 10% and Novo's international obesity-franchise sales grew 37%, partly driven by its newly launched oral Wegovy tablet.[3]
Guidance and share reaction: Novo raised its full-year outlook to 0% to −6% (from −12% to −4% previously) for adjusted sales and operating profit, yet shares fell around 5% on the day amid ongoing concern over US pricing pressure.[3]
Sources: Eli Lilly investor relations, CNBC, Yahoo Finance — 5–6 August 2026[1][2][3]
Trade press covering both results the following day described a "widening divide" between the two companies: according to Lilly's own earnings presentation, Lilly held 60.9% of the US obesity-and-diabetes drug market in Q2 2026, against Novo's 38.8%.[4]
| Metric | Eli Lilly | Novo Nordisk |
|---|---|---|
| Total quarterly revenue | ≈$23.0bn (+48% YoY) | ≈$12.1bn (beat forecast) |
| Core GLP-1-class franchise | ≈$14.8bn (Mounjaro + Zepbound) | ≈$9.16bn (Wegovy + Ozempic) |
| US obesity/diabetes market share | 60.9% | 38.8% |
| Full-year guidance direction | Raised: $85–87bn | Raised: 0% to −6% (from −12% to −4%) |
| Share-price reaction | Rose sharply | Fell ≈5% |
Table for research reference only; figures as reported in each company's Q2 2026 results and contemporaneous trade-press coverage.
What Does "Phase 3 Package Complete" Actually Mean for Retatrutide's Approval Timeline?
"Package complete" means Lilly has now generated all of the pivotal trial data it planned to submit in support of a marketing application — across the TRIUMPH obesity, diabetes and cardiovascular studies, plus the separate osteoarthritis and sleep-apnea trials.[1] It is a manufacturing- and data-readiness milestone, not a regulatory one: retatrutide still has to clear FDA filing (targeted Q1 2027) and formal review, which historically runs 10–12+ months for a biologic of this kind, before it could be approved.[4]
Reading the earnings news correctly. A complete Phase 3 package confirms Lilly has the clinical evidence in hand; it does not shorten the FDA's own review clock, and it does not change retatrutide's current status as investigational and unapproved.
1. Licensed, already-approved drugs
Tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy) are approved medicines whose Q2 2026 sales reflect real prescription volume.
2. Investigational pipeline compound
Retatrutide remains unapproved; "Phase 3 package complete" describes trial-data readiness for a future FDA filing, not a current approval.
3. Research-use reagent supply (what Velox Peptides does)
Both compounds are supplied strictly as HPLC-verified in vitro research reagents, entirely separate from either company's commercial drug supply or FDA filing status.
Does This Change Anything for Peptide Researchers or UK Research-Reagent Supply?
No. This is a quarterly financial-results announcement from two licensed pharmaceutical companies. It does not touch the UK regulatory position for research reagents under the Human Medicines Regulations 2012 — see our guide on whether research peptides are legal in the UK. It is, however, a useful marker of momentum: retatrutide's completed Phase 3 package is the clearest signal yet that Lilly's Q1 2027 BLA target is a manufacturing and documentation timeline rather than a data-readiness one.
Retatrutide and tirzepatide are supplied by Velox Peptides as research reagents only. They are not medicines and have not been evaluated by the MHRA or FDA. Not for human or veterinary use. See our Research Use Policy and MHRA Statement.
References
- Eli Lilly and Company. "Lilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progress." Press release, 5 August 2026. investor.lilly.com
- CNBC. "Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge." 5 August 2026. cnbc.com
- CNBC. "Novo Nordisk CEO defends economics of Wegovy pill as lower prices weigh on sales; shares fall 5%." 5 August 2026. cnbc.com
- CNBC. "Eli Lilly, Novo Nordisk earnings show widening divide in GLP-1 market." 6 August 2026. cnbc.com
- Yahoo Finance. "Novo Nordisk Q2 2026 earnings beat, raises full-year outlook." 5 August 2026. finance.yahoo.com
- Velox Peptides. "Why Did Lilly Delay Retatrutide's FDA Filing to 2027?" See our related coverage.
Frequently Asked Questions
Did Eli Lilly report new retatrutide news in its Q2 2026 earnings?
Yes. Alongside its 5 August 2026 second-quarter financial results, Eli Lilly confirmed that retatrutide's Phase 3 clinical data package is now complete for obesity, obstructive sleep apnea and knee osteoarthritis pain, supporting global regulatory submissions. Lilly's Biologics License Application (BLA) filing to the FDA remains targeted for Q1 2027, unchanged from prior guidance.
How much did tirzepatide (Mounjaro and Zepbound) sell in Q2 2026?
Worldwide Mounjaro revenue reached $9.9bn (up 91% year-on-year) and US Zepbound revenue reached $4.9bn (up 44%), a combined total of roughly $14.8bn for the quarter, according to Eli Lilly's 5 August 2026 second-quarter results release.
How did Novo Nordisk's Q2 2026 results compare?
Novo Nordisk reported Q2 2026 revenue of about $12.1bn, beating analyst forecasts, with its diabetes and obesity portfolio generating roughly $9.16bn - well below Lilly's combined $14.8bn+ from Mounjaro and Zepbound alone. US Wegovy injectable sales fell 22% at constant exchange rates even as Ozempic sales rose 10% and international obesity sales grew 37%. Novo shares fell around 5% on the day despite the revenue beat, on pricing-pressure concerns.
What does "Phase 3 package complete" mean for retatrutide's approval timeline?
It means Lilly now has all the pivotal trial data it planned to generate to support a marketing application, across the TRIUMPH obesity, diabetes, cardiovascular, sleep apnea and osteoarthritis studies. Lilly still needs to file the BLA (targeted Q1 2027) and complete FDA review, which historically takes 10-12+ months, so retatrutide remains investigational and unapproved as of this earnings report.
Does this earnings news change anything for UK peptide researchers?
No. This is a quarterly financial results announcement concerning two licensed pharmaceutical companies and their approved or investigational drugs. It has no bearing on the Human Medicines Regulations 2012, MHRA guidance, or the legal status of compounds supplied strictly as in vitro research reagents. Velox Peptides supplies retatrutide and tirzepatide as HPLC-verified research reagents only, unrelated to either company's commercial or regulatory activity.